Who Supplies Cephalexin to India from CYPRUS

To import finished pharmaceutical formulations containing Cephalexin into India, the foreign manufacturer must obtain a Drug Import License from the Directorate General of Foreign Trade (DGFT). The product must be registered with the Central Drugs Standard Control Organisation (CDSCO), which involves submitting Form CT-20/40/41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The registration process includes providing stability data in accordance with ICH Zone IV guidelines and ensuring compliance with the Indian Pharmacopoeia standards. The timeline for import drug registration can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory review process.

Imported Cephalexin formulations must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data must be provided, demonstrating the product's shelf-life under ICH Zone IV conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported products. The batch-wise testing ensures that each shipment meets the required quality standards before distribution in the Indian market.

Recent updates to CDSCO regulations have streamlined the import process for finished pharmaceutical formulations, reducing the time required for registration. The introduction of the Production Linked Incentive (PLI) scheme has impacted the import of finished formulations by encouraging domestic manufacturing. Bilateral agreements between India and Cyprus have facilitated smoother trade relations, including mutual recognition of Good Manufacturing Practices (GMP), which has simplified the import process for products like Cephalexin formulations.

India imports finished Cephalexin formulations to meet the demand for specific dosage forms and strengths not produced domestically. The market size for Cephalexin formulations in India is substantial, with a total import value of $349.5 million across 223 exporters to 104 countries. The import dependency arises due to the need for patented or branded formulations and specialized dosage forms that domestic manufacturers may not offer.

The Basic Customs Duty (BCD) for Cephalexin formulations under HS Code 30042012 is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is levied at 18% on the total value, including BCD and SWS. Anti-dumping duties may apply if the product is found to be dumped in the Indian market. Exemption notifications can reduce the total landed duty percentage, depending on the specific circumstances and compliance with applicable regulations.

Cyprus's pharmaceutical industry offers Cephalexin formulations that meet international quality standards, providing a competitive advantage in terms of product quality. While other suppliers like China, Germany, and the United States also export Cephalexin formulations to India, Cyprus's share in the Indian market is relatively small. The preference for sourcing from Cyprus may be due to factors such as adherence to GMP, product quality, and the ability to supply specific formulations not available from other sources.

India imports Cephalexin formulations from Cyprus due to the availability of specific dosage forms and strengths not produced domestically. Cyprus's adherence to international quality standards and GMP ensures the reliability and safety of the products. Additionally, Cyprus's ability to supply patented or branded formulations and specialized dosage forms that meet the unique needs of the Indian market makes it a preferred source.

When compared to other origins like China, Germany, and the United States, Cyprus offers competitive advantages in terms of product quality and regulatory compliance. While China and Germany may offer lower prices, Cyprus's commitment to quality and adherence to GMP standards provide a level of reliability that may justify the higher cost. The United States, while offering high-quality products, may have higher prices and longer lead times, making Cyprus a more attractive option for certain formulations.

Importing Cephalexin formulations from Cyprus involves certain risks, including single-source dependency, currency fluctuations, and potential regulatory changes. Quality incidents, although rare, can occur and may lead to shipment delays or rejections. Shipping disruptions, such as port congestion or logistical challenges, can also impact the timely delivery of goods. Historically, there have been no significant shortages reported in the supply chain for Cephalexin formulations from Cyprus.

1. 1Dual-Sourcing: Engage with multiple suppliers to mitigate the risk of supply chain disruptions.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential delays.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Payment (DA), or Documents Against Acceptance (DP), to manage financial risk.
4. 4Minimum Order Quantities (MOQs): Clarify MOQs with suppliers to ensure alignment with demand forecasts.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits and assessments of their manufacturing facilities and quality control processes.

1. 1DGFT Import License: Obtain an import license from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation.
3. 3Form CT-20/40/41: Submit the necessary forms for registration.
4. 4No Objection Certificate (NOC): Obtain an NOC from the Ministry of Health and Family Welfare.
5. 5Stability Data: Provide stability data in accordance with ICH Zone IV guidelines.
6. 6Indian Pharmacopoeia Compliance